Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Blood|May 22, 2016
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R Berenson, Alan Cartmell, Alberto Bessudo, et al.Blood|March 31, 2021
Acalabrutinib in treatment-naive chronic lymphocytic leukemiaJohn C Byrd, Jennifer A Woyach, Richard R Furman, et al.Blood Advances|May 16, 2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinibFarrukh T Awan, Anna Schuh, Jennifer R Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2020
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaPaolo Ghia, Andrzej Pluta, Malgorzata Wach, et al.Immunohorizons|June 3, 2025
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalizationPhillip Scheinberg, Matt R Khoshnevis, Philip A Robinson, et al.Journal of Hematology & Oncology|February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trialRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.Blood|March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinibClare Sun, Pia Nierman, Ellen K Kendall, et al.The Journal of Infectious Diseases|September 20, 2005
Molecular epidemiology of foodborne hepatitis a outbreaks in the United States, 2003Joseph J Amon, Rose Devasia, Guoliang Xia, et al.Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.Pageof 6